<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136863</url>
  </required_header>
  <id_info>
    <org_study_id>96-906-02-11</org_study_id>
    <nct_id>NCT01136863</nct_id>
  </id_info>
  <brief_title>Felodipine Event Reduction Study</brief_title>
  <acronym>FEVER</acronym>
  <official_title>Felodipine Event Reduction Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanxi Kangbao Pharmaceutical company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hypertension League Insititute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FEVER is an investigator-designed, prospective, multicentre,double-bind, randomized,
      placebo-controlled,parallel-group trial. The primary objective is to compare the long-term
      effects on the incidence of fatal and non-fatal stroke (and secondarily of other
      cardiovascular events) of administering a small dose of the calcium antagonist felodipine (5
      mg once a day) or of a placebo, in hypertensive patients whose blood pressure had
      preliminarily been reduced by administering a low-dose diuretic (hydrochlorothiazide,12.5 mg
      once a day) to be continued in association with felodipine or placebo, throughout the trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of fatal and non-fatal stroke</measure>
    <time_frame>During the study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause death</measure>
    <time_frame>during the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac event</measure>
    <time_frame>during the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cardiovascular events</measure>
    <time_frame>during the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new onset diabetes</measure>
    <time_frame>during the study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9800</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>felodipine group, active, pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>felodipine and HCTZ treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, no treatment, pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo and HCTZ group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Felodipine</intervention_name>
    <arm_group_label>felodipine group, active, pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo, no treatment, pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SBP of 210 mmHg or less and DBP less than 115 mmHg if under antihypertensive
             treatment; SBP 160-210 mmHg or DBP 95-115 mmHg if untreated. Presence of at least one
             or two risk factors or cardiovascular diseases Informed consent obtained

        Exclusion Criteria:

        stroke or myocardial infarction during the previous 6 months; secondary hypertension;
        unstable angina; cardiomyopathy or significant valvular disease; serum creatinine greater
        than 178 mmol/l (2.0 mg/dl); gout; uncontrolled diabetes(fasting plasma glucose &gt; 10
        mmol/l, 180 mg/dl despite therapy); serious pulmonary or hepatic disease; known
        contraindications to study drugs; unwillingness to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisheng Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Wai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fu Wai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>June 23, 2010</last_update_submitted>
  <last_update_submitted_qc>June 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Lisheng Liu/professor</name_title>
    <organization>Fu Wai Hospital, CAMS &amp; PUMC</organization>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>felodipine</keyword>
  <keyword>moderate to high risk patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Felodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

